The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: A double blind randomized study

Vitetta, Luis; Coulson, Samantha; Beck, Shoshannah L.; Gramotnev, Helen; Du, Sharon; Lewis, Sophie

doi:10.1016/j.ctim.2012.12.006

Cited by 52 publications

(61 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The in vitro antiviral activity of bLf against enveloped and naked DNA and RNA viruses has been widely demonstrated (Arnold et al, 2002;Berlutti et al, 2011;Di Biase et al, 2003;Lang et al, 2011;Marchetti et al, 1999;Ng et al, 2015;Nozaki et al, 2003;Pietrantoni et al, 2003;Puddu et al, 1998;van der Strate et al, 2001;Superti et al, 1997;Wakabayashi et al, 2014), while few papers have been published on its in vivo efficacy against viral infection (Chen et al, 2008;Egashira et al, 2007;Hirashima et al, 2004;Ishibashi et al, 2005;L et al, 2013;Lu et al, 1987;Moriuchi M, 2009;Okada et al, 2002;Shin et al, 2005;Tanaka et al, 1999;Ueno et al, 2006;Vitetta et al, 2013;Yen et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients:in vitroandin vivopreliminary evidences

Campione

Lanna

Cosio

et al. 2020

Preprint

View full text Add to dashboard Cite

The current treatments against SARS-CoV-2 have proved so far inadequate. A potent antiviral drug is yet to be discovered. Lactoferrin, a multifunctional glycoprotein, secreted by exocrine glands and neutrophils, possesses an antiviral activity extendable to SARS-Cov-2. We performed a randomized, prospective, interventional study assessing the role of oral and intra-nasal lactoferrin to treat mild-to-moderate and asymptomatic COVID-19 patients to prevent disease evolution. Lactoferrin induced an early viral clearance and a fast clinical symptoms recovery in addition to a statistically significant reduction of D-Dimer, Interleukin-6 and ferritin blood levels. The antiviral activity of lactoferrin related to its binding to SARS-CoV-2 and cells and protein-protein docking methods, provided the direct recognition between lactoferrin and spike S, thus hindering the spike S attachment to the human ACE2 receptor and consequently virus entering into the cells. Lactoferrin can be used as a safe and efficacious natural agent to prevent and treat COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients:in vitroandin vivopreliminary evidences

Campione

Lanna

Cosio

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Although the available evidence suggests that bLf is beneficial for H. pylori eradication (Recommendation Grade-A), unlike AMP derived from Lf [39], the extent of the documented benefit is small, and deserves further exploration. Other clinical trials on Lf are related to: (i) the prevention of hospital-acquired infections; (ii) the treatment of cystic fibrosis [40] in combination with hypothiocyanite; (iii) clinical efficacy against the common cold in combination with the IgG-rich fraction of whey proteins [41].…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine

Bruni¹,

et al. 2016

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs) represent a vast array of molecules produced by virtually all living organisms as natural barriers against infection. Among AMP sources, an interesting class regards the food-derived bioactive agents. The whey protein lactoferrin (Lf) is an iron-binding glycoprotein that plays a significant role in the innate immune system, and is considered as an important host defense molecule. In search for novel antimicrobial agents, Lf offers a new source with potential pharmaceutical applications. The Lf-derived peptides Lf(1-11), lactoferricin (Lfcin) and lactoferrampin exhibit interesting and more potent antimicrobial actions than intact protein.Particularly, Lfcin has demonstrated strong antibacterial, anti-fungal and antiparasitic activity with promising applications both in human and veterinary diseases (from ocular infections to osteo-articular, gastrointestinal and dermatological diseases).

show abstract

“…In biotechnology, the claim is not only for the protein content of the whey, but also for its therapeutic antiinflammatory proteins and immunoglobulins. For example milk lactoferrin has shown many protective and therapeutic characteristics like; ability to relieve cold symptoms in participants with the common cold, reduction of proliferation of cancer cells and protection against hepatitis virus (EsmailM et al, 2008;Habib et al, 2013;Vitetta et al, 2013). Immunoglobulin, a major components of milk and whey, showed some therapeutic and prophylactic characteristics against pathogenic and poisonous substances (Nusair and Tay, 2009;Yagil, 2013).…”

Section: Stability Of Antibodies and Proteins In Camel Whey Powder Trmentioning

confidence: 99%

Stability of antibodies and proteins in camel whey powder treated by Gamma-irradiation during radurisation process

Ahmad

Qawasmeh²,

Nusair³

et al. 2018

Emir J Food Agric

View full text Add to dashboard Cite

Camel milk and milk derived products have a growing potential in pharmacy, food and biotechnology industry. Its therapeutic value has been investigated and documented in many studies before. The contamination of camel whey powder during manufacturing and transportation may impact economy; re-pasteurisation could cause dramatic effect on antibodies and proteins of camel whey powder. Radurisation (0.4 to 10 kGy) process could be a choice in sterilising camel whey powder. This study aimed to investigate the stability of camel antibodies and proteins in whey powder before and after Gamma-irradiation. Efficacy of radiation dose on microbial content was also studied. Four batches of hyper immune camel whey powder containing antibodies against Propionibacterium acnes were subjected to six Gamma-radiation doses (1.5, 3, 4.5, 6, 7.5 and 9 kGy). Results revealed marked decline in the total microbial count (3-5 log cycles) after escalating the doses of irradiation. Minor effect on antibody activity (7.4 % reduction) was observed after treating the whey by 9 kGy. Moreover, the concentration of total camel IgG was reduced by 13% using the same irradiation dose. In addition, no effect on major whey proteins (Lactoferrin, Casein, and α-lactoalbumin) was revealed in protein identification using SDS-PAGE. In conclusion, using 9 kGy dose of Gamma-irradiation for sterilising camel whey powder is effectively reducing bacterial contamination with limited effects on antibodies activity and protein stability.

show abstract

The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: A double blind randomized study

Cited by 52 publications

References 16 publications

Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients:in vitroandin vivopreliminary evidences

Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients:in vitroandin vivopreliminary evidences

Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine

Stability of antibodies and proteins in camel whey powder treated by Gamma-irradiation during radurisation process

Contact Info

Product

Resources

About